AI Leaders Demand Gene Synthesis Oversight to Block Bioweapon Development

Leading AI company CEOs are urging Congress to mandate stronger screening protocols for synthetic DNA and RNA sales, as artificial intelligence has significantly lowered the technical barriers to designing dangerous pathogens. With large language models now capable of identifying gene synthesis sequences and guiding unauthorized procurement, regulatory safeguards have become critical to preventing bioterrorism and pandemic risks. This unified industry stance underscores the consensus that AI's dual-use threats require preemptive policy action.